



European Reference Network

for rare or low prevalence complex diseases

Network

Neuromuscular Diseases (ERN EURO-NMD)

L'ERN neuromusculaire à Paris


T EVANGELISTA; JA URTIZBEREA; H PASCAL



6ÈME JOURNÉE DE FILNEMUS; CITÉ INTERNATIONALE UNIVERSITAIRE DE PARIS 6-12-2019



complex diseases Network Neuromuscular



Finland

Norway

15 Italy

Expertise



European Reference Network for rare or low prevalence

omplex diseases

Neuromuscular Diseases (ERN EURO-NMD)

Specialist Disease Groups ORPHA 68381





Muscle

Peripheral Nerve







Motor Neuron



Mitochondrial Diseases

Expertise



European Reference Network

for rare or low prevalence complex diseases

Network Neuromuscular Diseases (ERN EURO-NMD)

Transversal Working Groups

















Imaging

Neurophysiologie

Pathology

Genetics

Research

Education

Ethics

PAB

Governance

NETWORK BOARD – Decision Making body 1 representative per HCP; PAB members

COORDINATOR

EXTERNAL ADVISORY BOARD

EXECUTIVE COMMITTEE

1 element from each of the **disease specialist groups** 1 element from each of the transversal working groups 1 representative from the CTSR

DAILY MANAGEMENT

COORDINATION OFFICE



Reference Network

for rare or low prevalence complex diseases

Network

Neuromuscular Diseases (ERN EURO-NMD)

Primary goals established in the ERN application

- 1. improve quality and equity of healthcare
- 2. enable the exchange of knowledge through teaching and training
- 3. facilitate translational research

- Focus on strengthening the collaboration amongst the 61 HCPs so that, when new members are proposed and endorsed, their integration is swift with minimum impact on the ERN's activities.



European Reference Network

for rare or low prevalence complex diseases

Network Neuromuscular Diseases (ERN EURO-NMD)

Action Plan for the next 3 years

2019-2021



for rare or low prevalence complex diseases

Network Neuromuscular Diseases (ERN EURO-NMD) Main Objectives

Education
 Clinical care
 Facilitate research



Education

ESTABLISH REGULAR THEMATIC WEBINARS

- Clinicians
- ✤Patients

There is a major role for the French Centres Proposing themes / speakers Diffusing the information Collaborate with FILNEMUS in a shared program ?



What are EURO-NMD webinars?

- Educational webinars
- Monthly basis
- Designed for healthcare professionals

Webinar Structure

- Last approximately 45' followed by 15' Q&A
- Hosted on Zoom software which allows, polls and live chat

Done in cooperation with the ERN RND Approved by the EAN





Education Other

Endorse/produce guidelines; work being done with the EAN and hopefully with the EPNS

Active participation and dissemination of the Paris Neuromuscular Summer School

Organise 1 thematic workshop/year (Themes to be proposed by the Board)

Fellowships



EDUCATION Fellowships

RULES:

- Affiliated to one of the 61 HCP
- Young research/clinician (<40 years of age) working in the field of NMD
- The scientific meeting you choose is in the field of NMD
- Candidates from ITC countries and those who would present a poster or a talk at the meeting will be favoured
- Short CV, a letter of intention
- Assessment: by the Exec. committee
- Invitation to attend Euro-NMD's annual meeting and present an overview of the meeting attended



CARE

Increase the use of the CPMS (e-Consultations)

- Operational Helpdesk
- Develop and implement disease-specific datasets
- Implementation of a scan bank and a bank for pathology images (integrated with the CPMS)

***** Work on guidelines and care pathways

 Each working group and the PAB to select themes and develop an action plan

***** Work on information for patients



The Clinical Patient Management System (CPMS)

Interaction with the French Centres mostly has experts for the panels

Or

es

Need to have an accurate knowledge of the expertise of the participants

Develop a CPMS training session in France under the umbrella of FILNEMUS (?)

https://cpms.ern-net.eu/k

European Reference



The Training Version of the CPMS

https://cpms-training.ern-net.eu/login/

Password: Cpmsern

Live CPMS: https://cpms.ern-net.eu/login/

You will need access to:

- -EU Login/ECAS
- -European Collaborative Platform
- -SaaS

UserName	KnownAs	Country		
euronmdcoord	euronmd coordinator	CZ		
euronmddatabase	euronmd database	BG		
euronmdguest	euronmd guest	BE		
euronmdhpuser1	euronmdhpuser1 testuser	ІТ		
euronmdhpuser2	euronmdhpuser2 testuser	HU		
euronmdhpuser3	euronmdhpuser3 testuser	DE		
euronmdhpuser4	euronmdhpuser4 testuser	FR		
euronmdhpuser5	euronmdhpuser5 testuser	FI		



Facilitate research

Dissemination of news ab

(newsletter, meetings, v

♦ERN Regist

Increase involvement

Collaboration with the

regarding collaborative projects

The ERN is a privileged tool to establish international networks and to facilitate additional funding

Cts

tabase)

Support suggestions from the new sh

ing groups



What direction would you like to see the ERN research activities go?

- Establish consortia and stimulate trans-national collaboration in research projects
- Clinical tool to help less privileged colleagues/patients; concentrate on helping with the CPMS
- Focused on the work within the working groups to try to get concrete projects favouring collaborative groups of research
- Getting funding and support for projects; increase the awareness about funding opportunities
- Improve collection of NH on rare neuromuscular diseases towards trial readiness
- · Develop meetings focused on selected topics, webinars



Facilitate research



Home	About us 🔻	EJP RD community	News	Events	Fundings and Calls 🔻	Platform of Data &	Resources	 Training and Empowerment
		Accelerated Translatio	n & Clinio	al Trials 🔻	EJP RD Newsletter	EJP RD Helpdesk	Careers	Privacy Policy

Fundings and Calls

EUROPEAN JOINT PROGRAMME RARE DISEASES

The EJP RD will foster annual Joint Transnational Calls (JTC) for collaborative research projects resulting in funding encompassing various research fields of rare diseases in continuation of previous E-Rare calls.

The EJP RD will also fund the Networking Support Scheme (NSS) to encourage sharing of knowledge on rare diseases and/or rare cancers between healthcare professionals, researchers, and patient advocacy organizations.

Furthermore, the EJP RD will also fund the Rare Diseases Research (RDR) Challenges which is an innovative funding scheme to foster private-public partnerships and multi-stakeholder collaborations.



Facilitate research




AIM

- (i) to solve large numbers of RD, for which a molecular cause is not known yet, by combined Omics approaches
- (i) to improve diagnostics of RD p web"

HCPs not yet involved in SOLVE-RD may become associated partners and establish an association agreement with the project coordinator



Registries Call





EURO-NMD is a learning and evolving network

- ERN monitoring
- Survey for values and services the ERN can provide
 Position statement papers on:
- ERN regis
- NGS usag
- Neonatal
- Overprice of repurposed drugs (ex Mexiletine)
 - Neonatal screening
 - NGS for diagnostic testing
- Mapping of existing resources



Your feed back is important

- 1. What services could/should the ERN provide to support you to provide care for patients?
- 2. What can the management team do to help improve de national status of your centre?
- 3. What other benefits can EURO-NMD create for you in your local hospital/ national health service?





For further details contact: info@ern-euro-nmd.eu



ern-euro-nmd.eu

CPMS help Desk: support@ern-euro-nmd.eu

"EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are **co-funded** by the European Union (Health Programme and CEF). For more information about the ERNs and the EU health strategy, please visit <u>ec.europa.eu/health/ern</u>"



6ème Journée de FILNEMUS; Cité Internationale Universitaire de Paris 6-12-2019

Secretariat for Euro-NMD

Paris

Project manager:



Heike Pascal

Project assistant: Annelies Herman





Newcastle


Communications

manager:



Michael Hails

Helpdesk assistant/CPMS: Chloe Blewitt



Building bridges and breaking barriers in rare neuromuscular diseases